Home › Neuroendocrine Tumors › Massachusetts › Boston
Neuroendocrine Tumors clinical trials in Boston, MA
5 studies for Neuroendocrine Tumors are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- Dana-Farber Cancer Institute, Boston
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
- Investigative Site, Boston
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
- Massachusetts General Hospital,, Boston
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RecruitingPhase 4
- Massachussets General Hospital, Boston
Neuroendocrine Tumors trials in other cities
- Philadelphia, PA11 studies
- Washington, DC11 studies
- Rochester, MN9 studies
- Houston, TX8 studies
- Chicago, IL7 studies
- Columbus, OH7 studies
- St. Louis, MO7 studies
- Detroit, MI7 studies
- Salt Lake City, UT7 studies
- Cleveland, OH7 studies
- Dallas, TX6 studies
- Cedar Rapids, IA6 studies
Other studies in Boston
- Breast Cancer112 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)85 studies
- Metastatic Cancer63 studies
- Colorectal Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.